Hosted on MSN14h
Nano-Cap MicroCloud Hologram's DeepSeek-Fueled Rally Poised To Continue: Retail Excitement Grows Amid Stock Rally
Shares of Shenzhen China-based MicroCloud Hologram, Inc. (HOLO) that defied the broader tech rout on Monday, are poised to ...
Deep5h
AI Companies Flock to Adopt DeepSeek R1 LLM
The DeepSeek R1 model has greatly strengthened the deep thinking ability of LLMs through a multi-stage loop training approach ...
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Candel Therapeutics Inc (CADL) 58.95% +44.69, ...
Jeffs' Brands Integrates DeepSeek AI To Boost E-Commerce Operations
Jeffs’ Brands Ltd JFBR revealed that its subsidiary, Fort Products Limited, has formed a partnership to incorporate the ...
1MTN : Vail Resorts Faces Leadership Shakeup Demand From Key Investor
Late Apex Partners, an investor in Vail Resorts, calls for major restructuring to address Vail's underperformance. LAP ...
CCN on MSN16h
Sam Altman Calls DeepSeek R1 ‘Impressive,’ Pat Gelsinger Adopts Model at Gloo Over OpenAI
Sam Altman has acknowledged the new OpenAI rival DeepSeek. Companies including Gloo have opted to use DeepSeek R1 instead of ...
How DeepSeek's fallout could threaten U.S. consumption, according to strategists
Citi strategists led by Adam Pickett and his team note how the U.S. equity market is "getting frothier," with what they call the current bubble growing more comparable to past bubbles. They aren't ...
IMAC Holdings, Inc.: IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC Holdings" or the "Company") has launched Ignite Proteomics LLC ("Ignite"), its new subsidiary dedicated to helping ...
SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that ...